Regeneron says its COVID-19 antibody cocktail shows promise in mild to moderate cases

The positive results enhance the antibody treatments case for an FDA emergency situation use permission, which the drugmaker sought Oct. 7.

” The very first job of an antiviral restorative drug is to lower the viral load, and our initial information in 275 patients strongly recommended that the REGN-COV2 antibody mixed drink might lower viral load and therefore possibly enhance scientific outcomes,” George Yancopoulos, MD, PhD, Regenerons president and chief scientific officer, stated in an Oct. 28 news release. “Todays analysis, involving more than 500 additional clients, prospectively verifies that REGN-COV2 can undoubtedly substantially decrease viral load and additional shows that these viral decreases are related to a significant decrease in the need for further medical attention.”.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.

More posts on drug store: Kroger-owned pharmacies offering in-store rapid COVID-19 antibody testsEli Lilly inks $375M offer with US to supply COVID-19 antibody drugSunstar remembers gingivitis drug due to potential bacterial contamination.

Katie Adams –
Thursday, October 29th, 2020
Print|Email.

Patients treated with the drug, called REGN-COV2, saw a 57 percent reduction in COVID-19- associated medical visits through day 29 of the trial.It also had a statistically substantial effect on reducing patients viral load over seven days, with impacts being most prominent in clients who had an especially high viral load.

Regenerons COVID-19 antibody cocktail significantly decreased the viral load and possibility of a medical visit for clients with mild to moderate cases of the illness, according to initial results from the drugmakers stage 2/phase 3 trial for the drug.